Moreover, a formulation containing sulforaphane and cyclodextrin reduced breast cancer stem cell viability in primary and metastatic ER+ samples from patients, through decreased ALDH positive population, the prevention of tamoxifen enrichment and the inhibition of metastasis and STAT3 activity [258]. The gene discussed is STAT3; the disease is breast carcinoma.